TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition

Presentations highlight the role of the Delta Opioid Receptor (DOR) as a novel target central to the regulation of multiple genes involved in immune suppression, chemotaxis and proliferation of immune suppressing cells in cancer and autoimmune disease including MDSCs, T regs, and M2 macrophages

TAMPA, Fla., Nov. 4, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it would present three posters on its research on the role of the Delta Opioid Receptor (DOR) in controlling the immunosuppressive capabilities of Myeloid-Derived Suppressor Cells (MDSCs) at the upcoming 68^th American Society of Hematology (ASH) Annual Meeting and Exposition taking place on December 12-15, 2026, in New Orleans, Louisiana.

"We continue to be impressed by uncovering the central role the DOR plays in proliferation, recruitment and immune suppressing capabilities across MDSCs, T regs and M2 macrophages, the 3 most important naturally occurring immune suppressing cells in the body. These immune suppressing cells are an important mechanism for the body to calm chronic inflammation, but when highjacked in the setting of cancer, they are known to be culprits in resistance to and failure of cancer immunotherapy," said Dr. James Bianco, President and Chief Executive Officer of TuHURA Biosciences. "In addition to providing information critical to multiple patent submissions, the data underscore the breadth of the potential therapeutic applications for DOR technology in the development of a first new class of non-tumor targeting, immune modulating ADCs."

Poster Presentation Details:

Abstract Number: 4725
Title: Inhibition of the delta opioid receptor (DOR) on myeloid-derived suppressor cells (MDSCs) significantly reduces Cxcl10, Saa3 and Acod1 gene expression, representing a single target to modulate MDSC proliferation, migration and immune suppression.
Presenter: Dr. Krit Ritthipichai, Director of Immunology
Session: 201. Granulocytes, Monocytes, and Macrophages: Poster III
Date and Time: Monday, December 14, 2026, 6:00pm to 8:00pm ET
Location: MCCNO – Hall F

Abstract Number: 4721
Title: Delta opioid receptor (DOR) inhibition drives both proenkephalin (PENK) gene expression and met-enkephalin (mENK) protein in tumor-derived myeloid-derived suppressor cells (tMDSC) and bone marrow-derived macrophage subtype 2 (BMDM2): Implications for modulation of immune suppression in cancer and autoimmune disease.
Presenter: Dr. Taekyoung Kwak, Lead Scientist, Immunology and Dr. Krit Ritthipichai, Director of Immunology
Session: 201. Granulocytes, Monocytes, and Macrophages: Poster III
Date and Time: Monday, December 14, 2026, 6:00pm to 8:00pm ET
Location: MCCNO – Hall F

Abstract Number: 4744
Title: Delta opioid receptor (DOR) inhibition drives both proenkephalin (PENK) gene expression and met-enkephalin (mENK) protein in tumor-derived myeloid-derived suppressor cells (tMDSC) and bone marrow-derived macrophage subtype 2 (BMDM2): Implications for modulation of immune suppression in cancer and autoimmune disease.
Presenter: Dr. Krit Ritthipichai, Director of Immunology
Session: 201. Granulocytes, Monocytes, and Macrophages: Poster III
Date and Time: Monday, December 14, 2026, 6:00pm to 8:00pm ET
Location: MCCNO – Hall F

About TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer.

TuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA has initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) compared to Keytruda® plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

In addition to its innate immune agonist product candidates, TuHURA is developing TBS-2025, its VISTA-inhibiting mAb in a Phase 1b clinical trial in patients with mutNPM1 r/r AML, a molecularly defined subgroup that represents approximately 35% of patients with AML. TuHURA is also leveraging its Delta Opioid Receptor technology to develop first-in-class, bi-specific, bi-functional antibody drug conjugates (ADCs) targeting Myeloid-Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

For more information, please visit www.tuhurabio.com and connect with TuHURA on Facebook, X, and LinkedIn.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain "forward-looking statements" within the meaning of, and subject to the safe harbor created by, Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases, you can identify these statements by forward-looking words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "should," "would," "project," "plan," "expect," "goal," "seek," "future," "likely," or the negative or plural of these words or similar expressions. Our statements in this press release regarding our ongoing DOR research program and studies are an example of such forward-looking statements. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include, among others, the risks associated conducting our early-stage DOR program, the ongoing Phase 3 study of IFx.20 and the general risks associated with continuing the development of IFx2.0 and TBS 2025; risks related to patient enrollment, trial design, data outcomes and regulatory interactions; uncertainty regarding the timing and likelihood of regulatory approvals; and the other risks described from time to time in detail in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed on March 31, 2026, and TuHURA's other reports and filings with the SEC from time to time, which are available on TuHURA's website and at www.sec.gov. 

The forward-looking statements and other information contained in this press release are made as of the date hereof, and TuHURA does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Investor Contact:
Monique Kosse
Gilmartin Group
[email protected]

SOURCE TuHURA Biosciences, Inc.